Entera Bio Ltd (ENTX)
NASDAQ:ENTX
ENTX Stock Chart & Stats
$1.03
-$0.11(-4.20%)
At close: 4:00 PM EST
$1.03
-$0.11(-4.20%)
Day’s Range― - ―
52-Week Range$0.98 - $3.22
Previous CloseN/A
Volume29.71K
Average Volume (3M)123.78K
Market Cap
$47.23M
Enterprise Value$45.20M
Total Cash (Recent Filing)$8.57M
Total Debt (Recent Filing)$211.00K
Price to Earnings (P/E)―
Beta0.33
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding45,857,243
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)9.88
Price to Sales (P/S)440.99
P/FCF Ratio-11.70
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue364.52
Enterprise Value/Gross Profit-5.65K
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$10.00Price Target Upside870.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership ExpansionThe expanded OPKO collaboration creates durable R&D and funding capacity by sharing 50% ownership and development costs for the LA‑PTH program. Joint ownership aligns incentives, reduces Entera’s single‑party cash burden, and accelerates development scale and regulatory readiness over the next 2–6 months and beyond.
Regulatory Progress For Lead AssetFDA agreement for a Phase 3 EB613 program and the broad qualification of BMD as an endpoint materially de‑risk the clinical pathway. This regulatory clarity supports a viable pivotal trial design, increases likelihood of efficient approval timeline, and preserves the commercial opportunity for an oral osteoporosis therapy.
Low Leverage And Stronger Equity BaseVery low debt levels and a materially larger equity base reduce short‑term liquidity risk and limit forced financing needs. This structural balance sheet strength gives management flexibility to pursue clinical milestones or partnerships without immediate leverage constraints, supporting multi‑quarter R&D execution.
Bears Say
Minimal And Declining RevenuePersistent minimal revenue emphasizes Entera’s current reliance on R&D milestones and partnerships rather than product sales. Over the next several quarters this limits internal cash generation, increases dependency on external funding or alliances, and raises execution risk if trials delay or partnerships change.
Sustained Negative Cash FlowOngoing cash burn near $7M annually is structural for a development biotech and will require further financing or partner funding to sustain pivotal trials. Even with some improvement versus prior year, continued negative FCF elevates dilution and execution risk if capital markets or partner commitments tighten over the medium term.
Negative Returns And Ongoing LossesDeep and persistent operating losses with negative ROE indicate ongoing value erosion absent successful clinical outcomes or commercialization. Over multiple quarters this increases the probability of equity dilution, constrains reinvestment capacity, and could pressure strategic options if trial results or approvals are delayed.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.98 and its highest was $3.22 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $47.23M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is May 08, 2026 which is in 41 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Mar 27, 2026. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.53.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 45,857,243 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of $0.44 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 9.709%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (870.87% Upside)
$10.00 (870.87% Upside)
Insider Transactions
Bought Shares
Worth $140.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 27.5%
Last 30 Days ▲ 27.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
-99.43%
Trailing 12-Months
Asset Growth
95.98%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(870.87% Upside)
Technical Analysis
Ownership Overview
3.25% Insiders
0.05% Mutual Funds
13.86% Other Institutional Investors
82.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---